Healthcare Asia Summit - March 25, 2026

Clinical Associate Professor Tan Hiang Khoon is a dynamic clinician leader who is currently serving as the CEO Singapore General Hospital. His career trajectory includes several key leadership roles within SingHealth. From 2021 to 2024, he served concurrently as Group Director of the International Collaboration Office (ICO) at SingHealth and Director of the SingHealth Duke-NUS Global Health Institute (SDGHI). Additionally, he took on the role of Deputy CEO (Future Health System), SGH from 2022 to 2024. Prior to these appointments, Dr Tan was the Chair of Surgery from 2015 to 2022.

With a distinguished career in head and neck surgery and surgical oncology, Dr Tan has made significant strides in healthcare leadership. He spearheaded the creation of the SingHealth Duke-NUS Head and Neck Disease Centre in 2013. As Chair of surgery, he led the integration of the Division of Surgery at Singapore General Hospital with the Division of Surgical Oncology at the National Cancer Centre Singapore to optimise care of surgical patients. Notably, during the COVID-19 pandemic, he established a 3,700-bed Community Care Facility, ensuring hospital capacities were maintained.

Dr Tan is dedicated to global health equity; he founded the Global Surgery Programme and initiated the Asian Surgical Leaders Network, which addresses the pandemic's impact on surgical health systems in Asia and develops strategies for health system resilience. His commitment to cost-conscious innovation led to a partnership with Duke University, resulting in a low-cost portable flexible nasopharyngoscope, enhancing diagnostic access in lower-resourced settings.

Dr Tan holds a medical degree from the National University of Singapore, a Ph.D. from the University of Bristol, and advanced training in head and neck surgical oncology from the Institute Gustave Roussy in Paris. He also earned an Executive Master in Business Administration from the National University of Singapore.

Beaver R. Tamesis, MD has been the President and Chief Executive Officer of Asian Hospital and Medical Center since November 1, 2022. Asian Hospital is part of Metro Pacific Health, the largest ne work of private hospitals in the Philippines.

A cardiologist by profession, Dr. Tamesis has been board-certified by the Philippine Heart Association
since 1991. He is internationally published in cardiology and structured treatment protocols for diabetes, and continues to actively practice at The Medical City, where he previously served as Training Officer for Internal Medicine and later founded the Cardiology Fellowship Training Program. He is a Fellow in good standing of both the Philippine College of Physicians and the Philippine College of Cardiology.

Before joining Asian Hospital, Dr. Tamesis served as Managing Director and President of Merck Sharp and Dohme (MSD) I.A. LLC, a leading multinational pharmaceutical company. Over his 27-year career with MSD, he held key roles including Medical Director, Business Unit Director for Bone and Joint and Cardio-Metabolic, and Regional Marketing Director for the launch of the diabetes drug JANUVIA. He led MSD Philippines from 2013 until his retirement in March 2022.

While at MSD, he also served as President of the Pharmaceutical and Healthcare Association of the Philippines (PHAP) from 2016 to 2021, following two years as Trustee. In this role, he championed et ical business practices, worked closely with the Department of Health and the media to combat medical disinformation—particularly around vaccines and COVID-19—and helped shape a rational approach to medicine pricing in the country.

Under his leadership, Asian Hospital and Medical Center has achieved sustained excellence and recognition both locally and internationally. The hospital was reaccredited by the Joint Commission International (JCI) in 2025, reaffirming its commitment to world-class quality and patient safety. It has also been a three-time Gold Award winner at the Hospital Management Asia (HMA) Awards for Clinical Effectiveness and Financial Improvement (2023–2025). In 2024, Dr. Tamesis received the HMA Excellence Award as Hospital CEO of the Year, recognizing his transformative leadership and organizational innovation.

Beyond HMA, Asian Hospital has been honored by the Healthcare Asia Awards for excellence in clinical service, patient care, management innovation, and workforce transformation; by the World Stroke Organization (WSO) Angels Awards for acute stroke care; and by the Anvil Awards with multiple Gold and Silver recognitions for outstanding communications and public relations programs. The hospital has also been named among the Philippines’ Best Employers by the Philippine Daily Inquirer.

In 2025, Dr. Tamesis was named CEO of the Year at the Philippines Leadership Awards and Philippines
Executive of the Year (Healthcare) at the Asian Management Excellence Awards. He was also included in the Asia CEO Awards’ Circle of Excellence as CEO of the Year—a testament to his vision, integrity, and unwavering commitment to advancing healthcare excellence in the Philippines.